Results 131 to 140 of about 2,262 (198)

Serial changes of NS5A P32deletion mutant in HCV genotype 1b patients after Daclatasvir/Asunaprevir failure

, 2018
Etsuko Iio, Shintaro Ogawa, Noritomo Shimada, Yuichiro Eguchi, Noboru Hirashima, Kentaro Matsuura, Yasuhito Tanaka   +6 more
openalex   +2 more sources

Response to therapy with direct antiviral drugs in HCV-infected patients with diabetes. [PDF]

Sci Rep
Brzdęk M, Zarębska-Michaluk D, Rzymski P, Lorenc B, Janocha-Litwin J, Berak H, Tomasiewicz K, Sitko M, Mazur W, Janczewska E, Dybowska D, Klapaczyński J, Parfieniuk-Kowerda A, Jaroszewicz J, Piekarska A, Flisiak R.   +15 more
europepmc   +1 more source

Hepatitis C: current treatments, emerging therapies and tackling health inequities on the path to global elimination. [PDF]

Clin Med (Lond)
Farooq HZ, Foster GR.
europepmc   +1 more source

Cost-Effectiveness Analysis For The Treatmet with Daclatasvir-Asunaprevir in Patients Naive with Chronic Hepatitis C Genotype 1b Without Baseline Ns5a Polymorphisms Under The Public Payer Perspective in Mexico [PDF]

, 2017
Clarissa Severino Gama, JM Benita, Jose Antonio Dela Peña Celaya   +2 more
openalex   +1 more source

Temporal Dynamics and Treatment Outcomes of Hepatitis C Virus/Human Immunodeficiency Virus Coinfection: A Multicenter Retrospective Study from South Korea. [PDF]

Gut Liver
Jeong JY, Yu SJ, Park J, Choi NR, Kim SS, Yoon JH, Eun HS, Choi J, Yoon KT, Jung YK, Park SY, Gwak GY, Kim TY, Kim DY, Kim DY, Kim JH, Lee JW, Jang JW.   +17 more
europepmc   +1 more source

Daclatasvir plus asunaprevir in treatment-naïve patients with hepatitis C virus genotype 1b infection

, 2018
Lai Wei, Fu‐Sheng Wang, Ming-Xiang Zhang, Jidong Jia, Alexey A. Yakovlev, Wen Xie, Eduard Burnevich, Jun-Qi Niu, Yong Jin Jung, Xiang-Jun Jiang, Min Xu, Xin-Yue Chen, Qing Xie, Jun Li, Jin-Lin Hou, Hong Tang, Xiao-Guang Dou, Yash Pragnesh Gandhi, Wen-Hua Hu, Fiona McPhee, Stephanie Noviello, Michelle A. Treitel, Ling Mo, Jun Hua Deng   +23 more
openalex   +1 more source

Engineering multiple levels of specificity in an RNA viral vector. [PDF]

Nat Commun
Chong LS, Kang J, Ince MH, Kim MS, Gao XJ, Elowitz MB.   +5 more
europepmc   +1 more source

Chronic Hepatitis C Treatment with Daclatasvir Plus Asunaprevir Does Not Lead to a Decreased Quality of Life

, 2018
Megumi Kawakubo, Yuichiro Eguchi, Michiaki Okada, Shinji Iwane, Satoshi Oeda, Taiga Otsuka, Syunya Nakashita, Norimasa Araki, Akemi Koga   +8 more
openalex   +2 more sources

HCV Antiviral Drugs Have the Potential to Adversely Perturb the Fetal-Maternal Communication Axis through Inhibition of CYP3A7 DHEA-S Oxidation. [PDF]

Drug Metab Dispos
Work HM, Hackett JC, Lampe JN.
europepmc   +1 more source

Improvement of Proteinuria due to Combination Therapy with Daclatasvir and Asunaprevir in Hepatitis C Virus-associated Renal Disease without Cryoglobulinemia

, 2018
Satoshi Takakusagi, Ken Sato, Yuhei Suzuki, Yuichi Yamazaki, Takashi Kosone, Satoru Kakizaki, Motoyasu Kusano, Hitoshi Takagi   +7 more
openalex   +2 more sources